Tagged Articles

Bayer 319 articles

J&J buys out Irish medtech company


One of Johnson & Johnson’s subsidiaries has snapped up Irish medtech company Neuravi in a deal that could be worth hundreds of millions of dollars. The consumer health care products and pharmaceutical giant’s DePuy Ireland subsidiary, an affiliate of Johnson & Johnson’s neurosurgery firm, Codman Neuro, purchased the company for an undisclosed sum. Neuravi manufactures a medical device called the EmboTrap that is used to retrieve blood clots in the brain following a stroke in order to restore blood flow to the vein. The device is used in the treatment of acute ischemic strokes, or blockages in the vessels supplying blood ... Read More

Former FDA chief to testify on Xarelto makers’ conduct


In January 2015, former Food and Drug Administration (FDA) Commissioner David Kessler testified in a Philadelphia court that five years before Johnson & Johnson subsidiary Janssen Pharmaceuticals added warnings to its antipsychotic Risperdal regarding a side effect involving disfiguring breast growth in adolescent boys, the company was aware of its danger to minors. It was the first bellwether trial among thousands involving claims that Janssen tried to cover up Risperdal side effects. Kessler testified that Risperdal “probably or very likely” triggered breast growth in boys – a condition called gynecomastia. He backed up that claim by referencing a 2001 study ... Read More

J&J blames disappointing 1Q sales on Invokana, Xarelto performance


Johnson & Johnson’s recently reported first quarter earnings report dropped more than 3 percent on the day the news was announced, a rarity for a fairly stable stock, according to NASDAQ analysts. The consumer health care and pharmaceutical giant is blaming the weak first-quarter earnings on price discounting in certain sales channels, as well as competition for the underperformance of its pharmaceuticals. Specifically, sales of J&J’s type 2 diabetes drugs Invokana and Invokamet fell almost 16.8 percent in the U.S. due to lower prices. The company’s blood thinner Xarelto, manufacturered in partnership with Bayer, saw a slight increase in prescription share, ... Read More

Key plaintiffs witnesses cleared for first Xarelto bellwether trial


U.S. District Judge Eldon E. Fallon admitted key witnesses for plaintiffs in the first two bellwether trials in the massive Xarelto multidistrict litigation (MDL) in Louisiana federal court. Fallon is overseeing 16,285 cases in the MDL in the Eastern District of Louisiana, the first of which is scheduled to begin next week. Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer fought to exclude or limit testimony from key plaintiff experts. But Judge Fallon ruled that four major experts were acceptable. Former Food and Drug Administration (FDA) Chief Medical Officer Dr. Suzanne Parisian, is also a physician, Board Certified Pathologist, past ... Read More

Lawsuits allege Xarelto is unreasonably dangerous in design


Johnson & Johnson’s Janssen Pharmaceuticals and Bayer face a potential $2.5 billion in potential liability over uncontrolled bleeding allegedly caused by their blockbuster blood thinner Xarelto. More than 16,000 cases are pending in a multidistrict litigation (MDL) in Louisiana, with the bellwether scheduled to start next week. U.S. District Judge Eldon E. Fallon shot down a preemption argument in a defense summary, which allowed state-law design-defect claims by those suing drug companies to move forward. Janssen and Bayer had argued that the defective design claims are preempted by federal law, and that it would be virtually impossible for them to ... Read More

First Xarelto bellwether trial to begin April 24


After two delays, the first lawsuit to stand trial in a massive multidistrict litigation (MDL) involving bleeding risks with the blood thinner Xarelto is scheduled for April 24. More than 15,000 lawsuits were consolidated in the Eastern District of Louisiana under Judge Eldon E. Fallon. The first bellwether case to go to trial involves the case of Joseph Boudreaux Jr., who says he took Xarelto to prevent strokes due to his heart condition, atrial fibrillation, and soon afterward suffered internal bleeding requiring multiple blood transfusions. His case will be heard in the Eastern District of Louisiana. Boudreaux’s trial will be ... Read More

Drug makers can’t skirt claims in first Xarelto bleeding risks trial


With just days before the first trial in the multidistrict litigation (MDL) involving bleeding risks with the top-selling blood thinner Xarelto is scheduled to begin, the Louisiana federal judge overseeing the lawsuits ruled that he would not drop some of the claims against the drug companies named in the suits. Johnson & Johnson’s Janssen Pharmaceuticals and Bayer argued that Food and Drug Administration (FDA) red tape was to blame for the lack of safety label updates or noncompliance with Louisiana law. U.S. District Judge Eldon Fallon also denied two motions for partial summary judgment citing federal preemption as a defense ... Read More

Parties argue over allowed testimony ahead of first Xarelto bellwether trial


The first bellwether trial in the massive multidistrict litigation involving bleeding risks with the blockbuster blood thinner Xarelto is scheduled to begin April 24, and already the courtroom is heating up. Johnson & Johnson’s Janssen Pharmaceuticals and Bayer are urging the Louisiana federal judge overseeing the trial not to accommodate the plaintiffs’ request to limit what the drug companies can testify about during the trial. Those suing Janssen and Bayer filed a motion last month asking to exclude non-relevant testimony that could prejudice their case, such as “suggestions about a verdict’s potential effect on the pharmaceutical industry, manufacturers’ incentive or ... Read More

Xarelto makers want to know if plaintiffs cases are funded by third parties


Johnson & Johnson’s Janssen Pharmaceuticals and Bayer, facing more than 1,200 cases in a mass tort over bleeding risks with their jointly produced blood thinner Xarelto, filed a motion requesting that the Philadelphia Court of Common Pleas force plaintiffs to reveal whether their lawsuits are being funded by a third party. The motion specifically targets cases that may be picked for the first wave of bellwether trials. If they are being financed, then the defendants want to know by whom. The defendants also requested access to any “third-party control, consultation, or funding” agreements. Currently, both parties are working to determine which ... Read More

Farxiga lawsuits consolidated by Judicial Panel on Multidistrict Litigation


The U.S. Judiciary Panel on Multidistrict Litigation (JPML) created a new product liability MDL involving over kidney-related injuries with the type 2 diabetes drug Farxiga. The 18 actions consolidated in New York are currently pending in six federal district courts and share common questions of fact that would benefit from a centralized pre-trial MDL docket, the JPML concluded. The lawsuits, waged at the makers of Farxiga, as well as its so-called sister drug Xigduo XR, Bristol-Myers Squibb Co. and AstraZeneca, allege that use of the diabetes medications can cause acute kidney injury and diabetic ketoacidosis, a serious condition in which ... Read More